For Immediate Release
Chicago, IL – March 31, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include BioShares Biotechnology Clinical Trials ETF (NASDAQ: BBC – Free Report ), Global X MSCI Argentina ETF (NYSEARCA: ARGT – Free Report ), iPath S&P 500 VIX Short-Term Futures ETN (NYSEARCA: VXX – Free Report ), iPath Bloomberg Natural Gas Subindex Total Return ETN (NYSEARCA:GAZ – Free Report ) and iPath Global Carbon ETN (NYSEARCA: GRN – Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Thursday’s Analyst Blog:
Best and Worst Zones of Q1 and Their ETFs
The rally in the global stock market continued with Trump-fueled optimism and expectation of faster growth. In fact, stocks scaled multiple highs on several occasions in the first quarter amid bouts of volatility. While hopes of reflation trade, robust Q4 earnings, and signs of improvement in Japanese, Chinese, and European economies led to bullishness in stocks, slew of elections in Europe, fears of political instability and expensive valuation keep investors cautious.
That said, most corners of ETF investing have performed exceptionally well while a few areas are lagging. Below, we have highlighted the best and worst zones of Q1 and their ETFs in detail:
Emerging market stocks have been on a tear this year with India leading the way higher. After being beaten down badly by the twin attacks of Donald Trump’s victory and currency demonetization last year, India’s stock market has made a stunning comeback this year. The landslide victory of Prime Minister Narendra Modi in a key state election, upbeat GDP data, and the Fed’s dovish outlook on future rates hike has renewed optimism in this emerging market lately.
Additionally, a slew of economic reforms, improving current account deficit, a rebound in agriculture, a recovery in private investment, introduction of the Goods and Services Tax (GST), and a fall in interest rates are fueling growth and driving stocks higher (read: 5 Reasons to Buy India ETFs Now ).
The healthcare sector has grabbed maximum investor attention and is the best performing sector of Q1 despite twist and turns. The surge has come on cheap valuation, robust earnings results, encouraging industry trends, and a slew of positive actions taken by the President. In particular, Trump has promised to reduce federal regulations by 75–80% and streamline the Food & Drug Administration’s (FDA) approval process. This would make it easier for biotech companies to bring new products to the market. Trump’s proposed tax reforms and cash repatriation policy also supported the rally.
Notably, BioShares Biotechnology Clinical Trials ETF (NASDAQ:BBC – Free Report ) is the showstopper with a 27.4% increase. It has a novel approach to biotechnology investing with exposure to companies that are in the clinical trials stage. This can easily be done by tracking the LifeSci Biotechnology Clinical Trials Index. BBC is a small cap centric fund, having amassed $24.4 million in its asset base. It charges 85 bps in fees per year from investors and trades in a light average daily volume of around 14,000 shares. Holding 70 stocks in its basket, it is widely spread out across various components with none holding more than 3.34% share. The fund has a Zacks ETF Rank of 3 or ‘Hold’ rating with a High risk outlook (read: Top ETF Stories of Q1 from Wall Street ).
Argentina is the top player of Q1 in Latin America thanks to hopes of an economic turnaround under President Mauricio Macri’s administration. The market-friendly government has promised to take the economy back to its growth path through a host of reforms after back-to-back years of near stagnation. As such, the lone Global X MSCI Argentina ETF (NYSEARCA:ARGT – Free Report ) targeting the country has risen nearly 21% this year.
The fund tracks the MSCI All Argentina 25/50 Index, holding 26 stocks in its basket. It is highly concentrated on the top two firms at 36.2% while the other firms hold less than 8.9% share. With respect to sectors, energy makes up for nearly one-third of the portfolio followed by double-digit exposure to technology and financials. The fund has managed $134.4 million in its asset base and trades in average daily trading volume of nearly 61,000 shares. It charges 74 bps in fees and expenses and has a Zacks ETF Rank of 3 with a Medium risk outlook.
Trump’s actions led to increased market uncertainty and political worries, but have not been able to break the bullish trend in the market. As a result, volatility products are the biggest losers in the first quarter. In particular, iPath S&P 500 VIX Short-Term Futures ETN (NYSEARCA:VXX – Free Report ) has tumbled 39.4%.
The ETN focuses on the S&P 500 VIX Short-Term Futures Index, which reflects implied volatility in the S&P 500 index at various points along the volatility forward curve. It provides investors with exposure to a daily rolling long position in the first and second months VIX futures contracts. The note has amassed $1 billion in AUM and charges 89 bps in fees per year. It sees a truly impressive volume of about 41.3 million shares a day (read: The Key Things to Know When Trading Volatility with ETFs ).
Overall, energy has underperformed throughout the first quarter with natural gas being the biggest laggard. This is because warmer weather dented heating demand for natural gas in winter and high stockpiles continued to weigh on demand. As a result, the ETFs tracking natural gas futures have been hit hard, with iPath Bloomberg Natural Gas Subindex Total Return ETN (NYSEARCA:GAZ – Free Report ) shedding nearly 33%.
The note delivers returns through an unleveraged investment in the natural gas futures contract plus the rate of interest on specified T-Bills. It follows the Bloomberg Natural Gas Subindex Total Return Index. The product is unpopular and illiquid with AUM of $4.8 million and average daily volume of 51,000 shares. Expense ratio comes in at 0.75%.
The renewable energy space has been badly hit as President Trump has promised to revive the downtrodden coal industry and scrap regulations. In this regard, Trump signed an executive order this week to roll back the Clean Power Plan – Obama's signature climate policy aimed at curbing carbon emissions (read: Trump Repeals Clean Power Plan: ETF Winners & Losers ).
This led to a steep decline of 27.6% iniPath Global Carbon ETN (NYSEARCA: GRN – Free Report ). The ETN follows the Barclays Global Carbon Index Total Return, which measures the performance of the most highly traded carbon-related credit plans. The note holds around 99.96% of its total assets in futures contracts of ECX Allowances (EUA) Emission and the remaining in futures contracts of ECX Certified Emission Reductions (CERs). The ETN has total assets of $0.7 million while volume is extremely light at around 9,000 shares a day. It charges investors 75 bps in fees and expenses.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on BBC - FREE
Get the full Report on ARGT - FREE
Get the full Report on VXX - FREE
Get the full Report on GAZ - FREE
Get the full Report on GRN - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BIOSH-BIO CLNCL (BBC): ETF Research Reports
GLBL-X MS ARGEN (ARGT): ETF Research Reports
IPATH-SP5 VX ST (VXX): ETF Research Reports
IPATH-BB NGAS (GAZ): ETF Research Reports
IPATH-GLBL CRBN (GRN): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research